Evidence map›Paper›PMID 37483604›Full record

ArticleFrontiers in immunology2023

Jaya Prakash Chalise, Ali Ehsani, Mengistu Lemecha, Yu-Wen Hung, Guoxiang Zhang, Garrett P Larson, Keiichi Itakura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jaya Prakash ChaliseCenter for RNA Biology and Therapeutics, Beckman Research Institute, City of Hope, Duarte, CA, United States.
Ali EhsaniCenter for RNA Biology and Therapeutics, Beckman Research Institute, City of Hope, Duarte, CA, United States.
Mengistu LemechaCenter for RNA Biology and Therapeutics, Beckman Research Institute, City of Hope, Duarte, CA, United States.
Yu-Wen HungImmunology and Theranostics, Beckman Research Institute, City of Hope, Duarte, CA, United States.
Guoxiang ZhangCenter for RNA Biology and Therapeutics, Beckman Research Institute, City of Hope, Duarte, CA, United States.
Garrett P LarsonCenter for RNA Biology and Therapeutics, Beckman Research Institute, City of Hope, Duarte, CA, United States.
Keiichi ItakuraCenter for RNA Biology and Therapeutics, Beckman Research Institute, City of Hope, Duarte, CA, United States.
City of Hope · USBeckman Research Institute

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

During B cell development in bone marrow, large precursor B cells (large Pre-B cells) proliferate rapidly, exit the cell cycle, and differentiate into non-proliferative (quiescent) small Pre-B cells. Dysregulation of this process may result in the failure to produce functional B cells and pose a risk of leukemic transformation. Here, we report that AT rich interacting domain 5B (

Indexed as

Precursor B-Cell Lymphoblastic Leukemia-LymphomaTranscription FactorsAnimalsCell ProliferationDNA-Binding ProteinsFatty AcidsHumansMicePrecursor Cells, B-LymphoidARID5B protein, humanArid5b protein, mouseDNA-Binding ProteinsFatty AcidsTranscription FactorsARID5BB-ALLB cell developmentfatty acid metabolismpre-B cells

Identifiers

PMID37483604
PMCPMC10360657
OpenAlexW4383557704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.